8th Annual Anti-Cancer Drug Discovery & Development Summit

[Guest guest]

Last Chance For Breakthrough Cancer Research Developments: 8th Annual

Anti-Cancer Drug Discovery & Development Summit, July 17-18, 2006

Main Category: Cancer / Oncology News

Article Date: 11 Jul 2006 - 0:00am (PDT)

Many researchers believe the key to combating cancer in the 21st

century will be through improved prevention, screening and early

detection of the disease. And surely they are correct as when colon

cancer is detected early, the cure rate is now 95 percent. Yet,

cancer research is the building block of understanding and treating

this wide-spread disease.

The 8th Annual Anti-Cancer Drug Discover & Development Summit, to be

held on July 17-18, 2006, will include the most prominent experts in

the field of cancer research as well as the latest anti-cancer

research on: 1) Targeted Therapeutics, 2) Antibody Derived Targets &

Biologics, and 3) Angiogenesis.

Highlighted research programs include the following:

-- Targeting VEGF Pathway with mAb's and Small Molecules

-- EGF Pathway Inhibitors (Erlotinib and Cetuximab)

-- Emerging Approaches to Target the c-Met/ HGF Axis

-- Selective and Multi-Targeted Kinase Inhibitors

-- Novel Biologicals (CD20, CTLA4, Angiopoietins, PSCA, SDF and Eph)

-- Emerging Data on Inhibitors of Mek, Hedgehog, CDK and HDAC

Complete list of participating companies and institutions includes:

Agensys, Amgen, Arqule, Array Biopharma, Astrazeneca, Chemokine

Therapeutics, Compound Therapeutics, Curagen, Curis, Dana-Farber

Cancer Institute, Exelixis, Genentech, Genmab A/S, Harvard

University, Hoffmann-La Roche, Immunogen, Ludwig Center for Cancer

Research, MD Cancer Center, Medarex, Medimmune, MIT, OSI

Pharmaceuticals, Pfizer, Sunesis, Sherris Pharma Partners, University

of Texas and Whitehead Institute.

Strategic Research Institute

http://www.srinstitute.com/cancer